Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica).
Stephanie A KleineChiara E HamptonChristopher SmithGenevieve BussieresPierre-Yves MulonReza SeddighiSherry CoxJoe SmithPublished in: Journal of veterinary pharmacology and therapeutics (2023)
Both pet and research pigs can suffer from some degree of pain from surgery, injuries, or osteoarthritis (OA). Despite this, there is a paucity of data on safe and effective analgesia agents in pigs. Grapiprant is an EP4 antagonist that blocks the action of the pro-inflammatory prostanoid, PGE 2 . It has shown efficacy in attenuating pain associated with ovariohysterectomy and OA in dogs. However, there are no data regarding grapiprant in pigs. Therefore, the pharmacokinetic profile of orally administered grapiprant to juvenile pigs (Sus scrofa domestica) was evaluated in this study. Seven juvenile pigs received 12 mg/kg grapiprant orally. Blood was collected from an indwelling jugular catheter using the push-pull method at set timepoints up to 48 hours. Sample analysis was performed with high-performance liquid chromatography. Mean grapiprant plasma concentration was 164.3 ± 104.7 ng/mL which occurred at 0.8 ± 0.3 h. This study demonstrated that grapiprant concentrations consistent with analgesia in dogs were reached at this dosage in pigs. Further studies are needed to evaluate the efficacy of grapiprant in pigs.
Keyphrases
- pain management
- high performance liquid chromatography
- chronic pain
- mass spectrometry
- minimally invasive
- rheumatoid arthritis
- electronic health record
- computed tomography
- knee osteoarthritis
- neuropathic pain
- big data
- spinal cord
- acute coronary syndrome
- postoperative pain
- machine learning
- high resolution
- data analysis
- simultaneous determination
- atrial fibrillation
- liquid chromatography